The issues addressed in this study are: What internal factors support changes in the international operations of new firms? and What effect do these changes have on the firm's structure, control system, and market performance. To answer these questions, this work examines the internal resources and market performance of a set of publicly traded biotechnology firms. Findings support the view that new firms can enter international markets through a variety of strategies, including international joint ventures and subsidiaries. Changes in international operations also are found to enhance firm market performance when accompanied by changes in firm structure and control systems. However, managers must be patient because market performance only improves significantly two years after these organizational changes have taken place.

The issues addressed in this study are: What internal factors support changes in the international operations of new firms? and What effect do these changes have on the firm's structure, control system, and market performance. To answer these questions, this work examines the internal resources and market performance of a set of publicly traded biotechnology firms. Findings support the view that new firms can enter international markets through a variety of strategies, including international joint ventures and subsidiaries. Changes in international operations also are found to enhance firm market performance when accompanied by changes in firm structure and control systems. However, managers must be patient because market performance only improves significantly two years after these organizational changes have taken place.

Most books on the biotechnology industry focus on scientific and technological challenges, ignoring the entrepreneurial and managerial complexities faced bio-entrepreneurs. The Business Models for Life Science Firms aims to fill this gap by offering managers in this rapid growth industry the tools needed to design and implement an effective business model customized for the unique needs of research intensive organizations. Onetti and Zucchella begin by unpacking the often-used ‘business model’ term, examining key elements of business model conceptualization and offering a three tier approach with a clear separation between the business model and strategy: focus, exploring the different activities carried out by the organization; locus, evaluating where organizational activities are centered; and modus, testing the execution of the organization’s activities. The business model thus defines the unique way in which a company delivers on its promise to its customers. The theory and applications adopt a global approach, offering business cases from a variety of biotech companies around the world.

This book is aimed at providing a large audience, including practitioners, politicians and decision-makers, with useful insights in relation to innovation and entrepreneurship in the biotechnology industry. It offers an international perspective and a set of theoretical lenses to underline the roles and the effects of entrepreneurship and scientific innovation as key factors to support new firm emergence and to achieve and maintain competitiveness in this so important industry. Alain Fayolle, EM Lyon, CERAG Laboratory, France and Solvay Business School, Belgium The biotechnology industry across the globe is growing dramatically in line with rapidly emerging scientific and technological developments. This book explores both the theoretical and practical aspects of entrepreneurship in the biotechnology industry, focusing on the innovation processes underpinning success for new biotechnology firms (NBFs). It argues that biotechnology is at a crossroads: to date the science has been solid, yet commercial success remains elusive, and that it will be the commercial success of NBFs which will dictate the long term viability of this crucial industry. The authors go on to examine the roles played by both entrepreneurship and innovation in the competitiveness of biotechnology companies through a focus on: intellectual property strategies, product development, valuing biotechnology ventures, funding innovation and R&D, alliances and networking, changing industry structures evidenced through the shifting value chain and the impact of globalization on the changing industry and organizational life cycles. International case studies with a focus on human biosciences support the important theoretical developments at the heart of this book. Innovation and Entrepreneurship in Biotechnology offers original and valuable insights to researchers, academics and students as well as to practitioners involved with innovation and entrepreneurship in the field of biotechnology.

This volume fills a gap in the international business literature, offering the perspectives of researchers who are deeply embedded in one key emerging market, India. With the global economy changing dramatically, firms from emerging markets are playing increasingly important roles in both outward and inward internationalisation. International Business Strategy offers profound insights into international business activities in this rapidly-evolving environment, in which multinational corporations from emerging markets are now influential players. Reflecting the complex nature of India itself, the chapters employ a variety of theoretical lenses to shed light on a wide range of issues encountered by Indian businesses, from some of the world’s largest corporations to small, entrepreneurial firms.

"The biotech industry is a complex, rapidly evolving, and critical industry. The industry holds great commercial and societal promise, but it is also filled with hype, confusion, and risks. Bergeron and Chan do a remarkable job of providing a sweeping insightful, and probing assessment of the current state and likely evolution of this global industry. This book is essential reading for the executive who desires a thorough understanding of this business and its potential."--John P. Glasser, Vice President and Chief Information Offers, Partners Healthcare System, Inc. "Bergeron and Chan have done a marvelous job integrating many different perspectives to give the reader a coherent road map of the biotech industry for the next decade. This powerful book is anchored by numerous relevant examples that create a framework which any life sciences professional needs to understand. Of particular note is the compelling assessment of the IT industry and its impact on the life sciences as these industries converge."--Michael A. Greeley, Managing General Partner, IDG Ventures. An in-depth examination of the growth and financing of the biotechnology industry worldwide Biotech Industry: A Global, Economic, and Financing Overview provides a thorough look at the current state of the biotechnology industry, including where major research is being conducted, where it's being applied, and where money and intellectual capital are flowing. Written by a renowned business columnist and an entrepreneurial scientist in the biotech area, this unique book gives Eos and other senior-level managers an understanding of Asia's pivotal role in the worldwide success of biotechnology commercialization, as well as insight into the biotech market over the next decade.